View Financial HealthSumitomo Pharma 配当と自社株買い配当金 基準チェック /06Sumitomo Pharma現在配当金を支払っていません。主要情報0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回り0.9%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Jan 31+ 1 more updateSumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024Nov 01Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023May 17+ 1 more updateUpcoming dividend of JP¥7.00 per share at 3.5% yield Mar 23Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Feb 01+ 1 more updateUpcoming dividend of JP¥14.00 per share Sep 22すべての更新を表示Recent updatesSumitomo Pharma Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Apr 22Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026Mar 03Sumitomo Pharma Co., Ltd. and Racthera Inc. Announce Scheduled Review in Japan of the Allogeneic Ips Cell-Derived Dopaminergic Neural Proenitor Cells (Amchepry)Feb 13Sumitomo Pharma Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026Nov 05Sumitomo Pharma Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025Sep 01Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Jul 31Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Jul 02Sumitomo Pharma Co., Ltd. to Report Q1, 2026 Results on Jul 31, 2025May 16Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 26, 2025May 13+ 1 more updateMarubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion.Apr 03Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Mar 01Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025Feb 01Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025Nov 10Second quarter 2025 earnings released: JP¥121 loss per share (vs JP¥72.68 loss in 2Q 2024) Nov 01Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)Sep 23Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanAug 07Less than half of directors are independent Aug 06New major risk - Share price stability Aug 03Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024Aug 02First quarter 2025 earnings released: EPS: JP¥40.11 (vs JP¥97.83 loss in 1Q 2024) Aug 01New minor risk - Share price stability Jun 03Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024May 24Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024May 16Full year 2024 earnings released: JP¥793 loss per share (vs JP¥188 loss in FY 2023) May 15Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024Mar 02Third quarter 2024 earnings released: JP¥126 loss per share (vs JP¥28.24 loss in 3Q 2023) Feb 02Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Jan 31+ 1 more updateSumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024Dec 15European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisNov 04Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Nov 03Second quarter 2024 earnings released: JP¥72.68 loss per share (vs JP¥96.63 loss in 2Q 2023) Nov 02Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024Nov 01New major risk - Share price stability Oct 31Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic HyperplasiaSep 12Now 22% undervalued after recent price drop Aug 30Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023Aug 06New minor risk - Share price stability Aug 04Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.Aug 02Now 28% undervalued after recent price drop Aug 01First quarter 2024 earnings released: JP¥97.83 loss per share (vs JP¥78.30 profit in 1Q 2023) Aug 01Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in SchizophreniaJul 31Sumitomo Pharma Co., Ltd. Announces Executive ChangesJul 11Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023Jun 28Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., LtdJun 24HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)Jun 23Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid CongressJun 10Full year 2023 earnings released: JP¥188 loss per share (vs JP¥142 profit in FY 2022) May 17Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023May 17+ 1 more updateSumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023May 16Upcoming dividend of JP¥7.00 per share at 3.5% yield Mar 23Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023Feb 03Third quarter 2023 earnings released: JP¥28.24 loss per share (vs JP¥24.94 profit in 3Q 2022) Feb 02Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Feb 01+ 1 more updateSumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023Dec 17Less than half of directors are independent Nov 16Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022) Nov 02Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Nov 01Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023Oct 07Upcoming dividend of JP¥14.00 per share Sep 22Now 20% undervalued Sep 17Sumitomo Pharma Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022Aug 02First quarter 2023 earnings released: EPS: JP¥78.30 (vs JP¥12.09 in 1Q 2022) Jul 31Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023Jul 30+ 1 more updateSumitomo Pharma Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022May 29Full year 2022 earnings released: EPS: JP¥142 (vs JP¥142 in FY 2021) May 15Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022May 13+ 2 more updatesLess than half of directors are independent Apr 27Less than half of directors are independent Apr 23Upcoming dividend of JP¥14.00 per share Mar 23Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational RealignmentMar 03Sumitomo Dainippon Pharma Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022Feb 08Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 02Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022Jan 31+ 1 more updateNow 22% undervalued after recent price drop Jan 26Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888Dec 15Investor sentiment deteriorated over the past week Nov 03Second quarter 2022 earnings released: EPS JP¥79.66 (vs JP¥47.92 in 2Q 2021) Oct 28Upcoming dividend of JP¥14.00 per share Sep 22Investor sentiment deteriorated over the past week Aug 05First quarter 2022 earnings released: EPS JP¥12.09 (vs JP¥45.96 in 1Q 2021) Jul 30Myovant Sciences and Pfizer Inc. Receives FDA Approval for MYFEMBREEMay 27Sumitomo Dainippon Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022May 14Full year 2021 earnings released: EPS JP¥142 (vs JP¥103 in FY 2020) May 13Sumitomo Dainippon Pharma Co., Ltd Announces That They Will Initiate A Phase 1 Clinical Study of Dsp-0038 in the United States for the Treatment of Alzheimer’S Disease PsychosisMay 13Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year 2022May 12Sumitomo Dainippon Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2021Apr 24Upcoming dividend of JP¥14.00 per share Mar 24New 90-day high: €14.90 Mar 11Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers, Effective from April 1, 2021Feb 26Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year Ending March 31, 2021Feb 12Sumitomo Dainippon Pharma Announces Topline Results of Phase 3 Study on Napabucasin Fails to Reach Primary Endpoints in Colorectal CancerFeb 09決済の安定と成長配当データの取得安定した配当: DPMの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DPMの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Sumitomo Pharma 配当利回り対市場DPM 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DPM)0%市場下位25% (DE)1.6%市場トップ25% (DE)4.5%業界平均 (Pharmaceuticals)2.8%アナリスト予想 (DPM) (最長3年)0.9%注目すべき配当: DPMは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DPMは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DPM German市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: DPMが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 09:50終値2026/04/30 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sumitomo Pharma Co., Ltd. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Atsushi SekiBarclaysRitsuo WatanabeBofA Global ResearchHidemaru YamaguchiCitigroup Inc14 その他のアナリストを表示
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Jan 31+ 1 more update
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024Nov 01
Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023May 17+ 1 more update
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Feb 01+ 1 more update
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026Mar 03
Sumitomo Pharma Co., Ltd. and Racthera Inc. Announce Scheduled Review in Japan of the Allogeneic Ips Cell-Derived Dopaminergic Neural Proenitor Cells (Amchepry)Feb 13
Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Jul 31
Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Jul 02
Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion.Apr 03
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025Feb 01
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanAug 07
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Jan 31+ 1 more update
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of EndometriosisNov 04
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®Nov 03
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024Nov 01
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic HyperplasiaSep 12
Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.Aug 02
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in SchizophreniaJul 31
Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., LtdJun 24
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)Jun 23
Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid CongressJun 10
Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023May 17+ 1 more update
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023Feb 01+ 1 more update
Second quarter 2023 earnings released: JP¥96.63 loss per share (vs JP¥79.66 profit in 2Q 2022) Nov 02
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Nov 01
Sumitomo Pharma Co., Ltd. Provides Impairment Loss Guidance for the Second Quarter of the Fiscal Year Ending March 31, 2023Oct 07
Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023Jul 30+ 1 more update
Sumitomo Dainippon Pharma Announces Personnel Changes Including Representative Director and Organizational RealignmentMar 03
Sumitomo Dainippon Pharma Co., Ltd. Provides Financial Guidance for the Year Ending March 31, 2022Jan 31+ 1 more update
Sumitomo Dainippon Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2022May 14
Sumitomo Dainippon Pharma Co., Ltd Announces That They Will Initiate A Phase 1 Clinical Study of Dsp-0038 in the United States for the Treatment of Alzheimer’S Disease PsychosisMay 13
Sumitomo Dainippon Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2021Apr 24
Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers, Effective from April 1, 2021Feb 26
Sumitomo Dainippon Pharma Co., Ltd. Revises Earnings Guidance for the Year Ending March 31, 2021Feb 12
Sumitomo Dainippon Pharma Announces Topline Results of Phase 3 Study on Napabucasin Fails to Reach Primary Endpoints in Colorectal CancerFeb 09